Sign Up to like & get
recommendations!
1
Published in 2023 at "Medicina"
DOI: 10.3390/medicina59040659
Abstract: Background and Objectives: TPO-RAs (romiplostim/eltrombopag/avatrombopag) have broadly demonstrated high efficacy rates (59–88%), durable responses (up to three years) and a satisfactory safety profile in clinical trials. The effect of TPO-RAs is classically considered to be…
read more here.
Keywords:
treatment srot;
tpo ras;
tpo;
sustained remission ... See more keywords